Compare · ABT vs EWTX
ABT vs EWTX
Side-by-side comparison of Abbott Laboratories (ABT) and Edgewise Therapeutics Inc. (EWTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and EWTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $154.15B, about 41.1x EWTX ($3.75B).
- Over the past year, ABT is down 33.2% and EWTX is up 154.1% - EWTX leads by 187.3 points.
- EWTX has been more active in the news (13 items in the past 4 weeks vs 8 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 15 for EWTX).
- Company
- Abbott Laboratories
- Edgewise Therapeutics Inc.
- Price
- $88.42-0.03%
- $36.77+5.78%
- Market cap
- $154.15B
- $3.75B
- 1M return
- -0.48%
- +17.06%
- 1Y return
- -33.21%
- +154.11%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 13
- Recent ratings
- 25
- 15
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Edgewise Therapeutics Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
Latest ABT
- SEC Form 11-K filed by Abbott Laboratories
- Abbott declares 410th consecutive quarterly dividend
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
Latest EWTX
- SEC Form 4 filed by Director Brege Laura
- SEC Form 4 filed by Director Thompson Peter A.
- SEC Form 4 filed by Director Morris Arlene
- SEC Form 4 filed by Director Edris Badreddin
- SEC Form 4 filed by Director Martin Christopher Nathan
- SEC Form 4 filed by Director Fox Jonathan C
- Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum
- Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
- Edgewise Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules